Daniel J Safer1, Julie Magno Zito. 1. Johns Hopkins University School of Medicine, Baltimore, Maryland 21218, USA. dsafer@jhmi.edu
Abstract
OBJECTIVE: The aim of this study was to report the frequency of common treatment-emergent adverse events (AEs) from selective serotonin reuptake inhibitors (SSRIs) in children, adolescents, and adults. METHOD: AE data were obtained from all published double-blind, placebo-controlled SSRI studies of children and adolescents that separated AE findings by age group. The AE findings were pooled for purposes of age-group comparisons. Double-blind, placebo-controlled SSRI studies of adolescents (n = 2) and of adults identified in systematically identified trials (n = 22) were assessed to compare patterns and rates across the age span. Other reports, primarily from the published SSRI literature, were added to clarify the findings presented. RESULTS:Activation and vomiting SSRI AEs were 2- to 3-fold more prevalent in children than in adolescents, and their rate was lowest in adults. Somnolence as a SSRI AE was uncommon in children; its rate increased with advancing age. Insomnia and nausea were common SSRI AEs across the age span. Activation AEs were a frequent reason for discontinuation from SSRI clinical trials in preadolescents, whereas somnolence, nausea, and insomnia AEs were the most common reasons for trial discontinuations in adults. CONCLUSIONS: Children are particularly vulnerable to specific AEs from certain medications, such as SSRIs. It is likely that the level of children's biological immaturity explains part of this phenomenon.
RCT Entities:
OBJECTIVE: The aim of this study was to report the frequency of common treatment-emergent adverse events (AEs) from selective serotonin reuptake inhibitors (SSRIs) in children, adolescents, and adults. METHOD: AE data were obtained from all published double-blind, placebo-controlled SSRI studies of children and adolescents that separated AE findings by age group. The AE findings were pooled for purposes of age-group comparisons. Double-blind, placebo-controlled SSRI studies of adolescents (n = 2) and of adults identified in systematically identified trials (n = 22) were assessed to compare patterns and rates across the age span. Other reports, primarily from the published SSRI literature, were added to clarify the findings presented. RESULTS: Activation and vomiting SSRI AEs were 2- to 3-fold more prevalent in children than in adolescents, and their rate was lowest in adults. Somnolence as a SSRI AE was uncommon in children; its rate increased with advancing age. Insomnia and nausea were common SSRI AEs across the age span. Activation AEs were a frequent reason for discontinuation from SSRI clinical trials in preadolescents, whereas somnolence, nausea, and insomnia AEs were the most common reasons for trial discontinuations in adults. CONCLUSIONS:Children are particularly vulnerable to specific AEs from certain medications, such as SSRIs. It is likely that the level of children's biological immaturity explains part of this phenomenon.
Authors: Adam M Reid; Joseph P H McNamara; Tanya K Murphy; Andrew G Guzick; Eric A Storch; Wayne K Goodman; Gary R Geffken; Regina Bussing Journal: J Psychiatr Res Date: 2015-10-14 Impact factor: 4.791
Authors: Moira A Rynn; John T Walkup; Scott N Compton; Dara J Sakolsky; Joel T Sherrill; Sa Shen; Philip C Kendall; James McCracken; Anne Marie Albano; John Piacentini; Mark A Riddle; Courtney Keeton; Bruce Waslick; Allan Chrisman; Satish Iyengar; John S March; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-12-31 Impact factor: 8.829
Authors: Sarah A Crawley; Nicole E Caporino; Boris Birmaher; Golda Ginsburg; John Piacentini; Anne Marie Albano; Joel Sherrill; Dara Sakolsky; Scott N Compton; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; John March; John T Walkup; Philip C Kendall Journal: Child Psychiatry Hum Dev Date: 2014-08